

Cancer Test Requisition Form (Comprehensive) - Page 1 of 3

COMPLETE ENTIRE FORM AND SUBMIT PEDIGREE/CLINIC NOTES TO AVOID DELAYS

To submit an order via email, please send the completed test requisition form to info@ambrygen.com

COLLECTION DATE (REQUI	RED)				requis	JICIOII I	orm to imowaribrygen.com
If date of collection is not provided, three cal- specimen receipt will be used (for specimen	s stored longer than 30	PLEASE SUBMIT THE FOLLOWING WITH THE TRF:					
days, the day of archive retrieval will be used	as the date of service)		1. Clinic Notes	2. Pedigree	3. Insurance Car	d and <i>i</i>	Authorization Documents
PATIENT INFORMATION				D			() ()
Legal Name (Last, First, MI)				Date of Birth (MM,	/DD/YY) Sex Assigned at Birth ☐ F ☐ M	□Ma	er (optional) an □ Woman □ Nonbinary ff-described
Genetic Ancestry: ☐ Ashkenazi Jew☐ Middle Eastern☐ Native Americ					□ Mediterranean		MRN
Address			City		St	ate	Zip
11 11 11		le a					
Mobile #		Email					
SPECIMEN INFORMATION	(Please see ambryge	n.com/specimen-require	ements for details)				
☐ Personal history of allogenic bone	marrow or periphera	l stem cell transplant					
Specimen ID			Medical Record #				
Collection Assistance: Phlebotomy	draw* ☐ Send saliva	kit to patient	l				
* As the patient's clinician, I am unawa patient if the safety of the phlebotomist	t and/or patient(s) are	in question.			stand that the phlebotomi	st has ful	l authority to refuse to draw any
ORDERING LICENSED PROV				y of the report)			
Facility Name (Facility Code)		Address	City		State / Country	Zip	Phone
Ordering Licensed Provider Name (L	ast, First)(Code)	NPI#	Phone	Fa	x/Email		
Additional Results Recipients		5	21 (5 (5				
Genetic Counselor or Other Medical	Provider Name (Last	t, First) (Code)	Phone/Fax/Em	aıl			
Genetic Counselor or Other Medical	Provider Name (Last	t, First) (Code)	Phone/Fax/Em	ail			
CONFIRMATION OF INFORM The undersigned person (or represer consent. I confirm that testing is med genetic counseling services by a third applies to the attached letter of med	ntative thereof) ensur dically necessary and d-party service, as rec	res he/she is a licensed n that test results may im	nedical professional author pact medical management	ized to order genet for the patient. I as	ic testing and confirms gree to allow Ambry Ger	that the netics to	patient has given appropriate facilitate the provision of pre-test
Signature Required for Processing	<u> </u>	ional Signature:				D	ate:
■ INSURANCE BILLING (Inclu	ude copy of both side	es of insurance card)			☐ INSTITUTIONAI	L BILLI	NG
Patient Relation to Policy Holder?	Name and DOB of				Facility Name		d invoice to facility address above
Self Spouse Child	Policy Holder (if no Policy #	ot self)	НМО		Address		
Company	Folicy #		Auth #		Address		
Special Billing Notes:					Contact Name		
					Phone Number		E-mail/Fax
					☐ PATIENT PAYM	FNT	
				-			s) Credit Card (Call 949-900-5795)
Patient Acknowledgement: I acknowledge (Ambry), authorize Ambry to release me medical records for this purpose. I understood in agree to be contacted regarding future reprivacy practices at https://www.ambrygen. For patient payment by credit card: I her please provide the total annual gross howerify the above information for the sole.	dical information conce stand that I am financia esearch studies for which com/legal/notice-of-priv reby authorize Ambry G usehold income: \$	erning my testing to my insu- lly responsible for any amou I may be a candidate. Any fut acy-practices. ienetics Corporation to bill r	rer, to be my designated repre unts not covered by my insurer ure research projects will be subj my credit card as indicated abo mily members in the househol	esentative for purpos r and responsible for lect to a separate infor ove. In order to expec d supported by the li	es of appealing any denial of sending Ambry money recomed consent process and partite consideration for eligib	of benefits eived fron rticipation ility for Ai	s as needed and to request additional in my health insurance company. is voluntary. Learn more about Ambry's inbry's Patient Assistance Program,
For NY Residents: By checking this box, I agree that Ambry Genetics must discard my samp					ot checking this box, I unc	derstand t	that under New York State law,
Patient Signature (I agree to terms							Date:



Patient Name: DOB:

Cancer Test Requisition Form (Comprehensive) - Page 2 of 3

INDICATIONS FOR	TESTING (Ch	eck all that app	ly)					
ICD-10 code(s):								
Testing could aid in sy	stemic therap	y and/or surg	ical decision-ma	king for my affecte	d patien	nt □ Yes □ No □ STA ⁻	Γ TEST: Date resi	ults needed (if known):
Was genetic counseli	ng completed	? □ Yes □ N	lo 🗌 Unknown	Date Genetic Co	ounselir	ng was Performed:		
PATIENT CLINICAL	HISTORY							
☐ No personal history	of cancer							
Cancer/Tumor	Age at Dx	Pathology an	d Other Info					
Brain tumor								
Breast		Type:		ER□(+) □(-)	□unk	PR□(+) □(-) □unk	HER2/neu□(+)
2nd primary breast		Type:		ER□(+) □(-)	□unk	PR□(+) □(-) □unk	HER2/neu□(+) (-) unk Metastatic: Y N
Colorectal		Location:						
Melanoma								
Ovarian		☐ Fallopian t	ube 🗌 Primary	peritoneal				
Pancreatic								
Prostate		Gleason Scor	re:				Meta	static: 🔲 Y 🔲 N
Uterine								
Hematologic		Туре:		□Alloge	enic bon	ne marrow or peripheral	stem cell transpl	ant^
Other Cancer		Туре:						
Charlan		Adenomat	ous	Pe	olyp #:[□1 □2-5 □6-9 □10	-19 🗆 20-99 🗀	100+
GI polyps		☐ Other type	2:	P	olyp #:[□1 □2-5 □6-9 □10)-19 2 0-99 	100+
Other clinical history:								
Blood/saliva from patients with a history of allogenic bone marrow or stem cell transplant cannot be used for genetic testing. Blood/saliva from patients with a ctive hematological								
	recommended. An alternative specimen may be needed. Please see ambrygen.com/specimen-requirements for details ESTING HISTORY (Please include copies of any previous test results)							
☐ No previous molecu			ples of any previou	is test results/				
·								
		s) performed: Microsatellite instability analysis: Stable (MSS) Unstable/high (MSI-H) Unstable/low (MSI-L)						
Result (s):		Stable (MSS) Unstable/high (MSI-H) Unstable/low (MSI-L)						
☐ Somatic test/tumo	r profile Test	(s) performed	:			C, if multiple primaries, to	umor used:	
Result(s):		☐ Proteins present: ☐ Proteins absent: ☐						
FAMILY HISTORY								
Completing this section is r	not mandatory for	r ordering if a pe	digree and/or clinica	l note with family histo	ry is supp	olied, but is recommended and	helps with results in	nterpretation and claims filing.
Family History of Cancer:	Yes No (if	yes, please pro	vide relative inforn	nation below.)	Patient	Testing and Cancer Type D	etails:	
Relationship to Patient	Materna	al Paternal	Age at Each Dx	Family Testing and	Cancer T	ype Details		If Relative Has Not Been Tested, Why? (select option)
				Cancer type(s):				Deceased
				Pathology Details:				☐ Declines Testing
				Testing Details: Cancer type(s):				□ No Contact □ Deceased
				Pathology Details:				☐ Declines Testing
				Testing Details:				□ No Contact
				Cancer type(s):				□ Deceased
				Pathology Details: Testing Details:				☐ Declines Testing ☐ No Contact
				Cancer type(s):				Deceased
				Pathology Details:				☐ Declines Testing
				Testing Details:				☐ No Contact



Patient Name:	DOB:
---------------	------

Cancer Test Requisition Form (Comprehensive) - Page 3 of 3

For multiple tests, testing will be run concurrently (initiated at the same time) unless otherwise specified. For reflexive testing (second test starts pending first test outcome), indicate the order of reflexive tests in the notes section or next to the test check box. For reflex test orders, any positive findings (pathogenic/likely pathogenic) in the first test will be reported, and the second test will be cancelled; all other findings will automatically reflex (including VUS).

reported, and the second test will be cancelled, all other findings will dutomatically reflex (including vOS).									
CANCER TEST ORDERS									
Primary	Test Ord	ler							
! REC	QUIRED: S	Select a Primary Test Order							
For Patie	nts Mee	ting BRCA1/2 Testing Crit	eria	For Patients Meeting Colorectal Cancer Syndrome Testing Criteria (polyposis)					
□ BRCA1,	/2 test			Polyposis	test: 🗌	APC/MUTYH			
For Patie	nts Mee	ting Colorectal Cancer Syi	ndrome Testing Criteria (Lynch)	Other:					
Lynch Syn	drome te	est: MLH1, MSH2, MSH6,	PMS2, EPCAM	☐ None o	of the abo	ove (patient does not meet a	ny genetic testing criteria)		
Select an	Option	al Supplemental Test (Per	payer policy, all tests in this section will b	e process	ed and b	pilled separately; tests may	be performed as a reflex.)		
Order	Test Code	Test Name	Description	Order	Test Code	Test Name	Description		
	8857	BRCANext®	19 gene breast & gynecologic cancer test		8821	ColoNext®	20 gene colorectal cancer & polyposis test		
	I	Add on: ☐ Limited Evidence	(Additional 7 genes)			Add on: ☐ Limited Evidence	(Additional 6 genes)		
	8836	BRCAPlus®	13 gene STAT breast management test						
	8824	CancerNext®	39 gene pan-cancer test			CustomNext-Cancer® Notes:	up to 90 gene custom test		
	8875	CancerNext-Expanded®	76 gene pan-cancer test		9511	Notes.	Gene content is required. Use CustomNext-		
		Add on: ☐ Limited Evidence	(Additional 9 genes)				Cancer supplemental form for guidance.		
		Add on: Pancreatitis (Add	litional 5 genes)						
		I] [
Other Su	pplemei	ntal Test Options (Select	f applicable)						
□+RNAir	nsight® (Not available with BRCAplu	s, or STAT orders; PAXgene® tube required fo	r RNA)					
Order	Test Code	Test Name	Description	Order	Test Code	Test Name	Description		
Heredita		t and/or Ovarian Cancer		Genitou	urinary C	Cancer			
	9014	ATM	Ataxia-telangiectasia		9044	BAP1			
	8838	BRCA1/2	BRCA1/2-associated hereditary breast and		6301	FH	Hereditary leiomyomatosis and renal cell cancer		
	5892	BRCA1/2 Ashkenazi Jewish 3-site mutation panel	ovarian cancer (HBOC)		5921	FLCN	Birt-Hogg-Dubé syndrome		
	9016	CHEK2			2606	VHL	Von-Hippel Lindau disease		
	5260	DICER1			5904	TSC1 and TSC2	Tuberous sclerosis complex		
	2366	PALB2			ine Tumo		ruberous seletosis complex		
	2106	PTEN	PTEN-related disorders		2646	MEN1	Multiple endocrine neoplasia type 1		
			(including Cowden syndrome)		2680	RET gene sequence	Multiple endocrine neoplasia type 2		
	2866	TP53	Li-Fraumeni syndrome		cin Cancer/Melanoma				
Gastroin	3040	_ancer APC	Familial adenomatous polyposis		4708	CDKN2A and CDK4	Familial atypical multiple mole		
	8726	APC and MUTYH	Familial adenomatous polyposis Adenomatous polyposis	 	4700	concurrent	melanoma (FAMMM)		
	8604	BMPR1A and SMAD4	Juvenile polyposis syndrome		5684	PTCH1	Gorlin syndrome		
	4726	CDH1	Hereditary diffuse gastric cancer			ry Cancer Testing	I		
	8519	EPCAM del/dup	Lynch syndrome		5704	NF1	Neurofibromatosis type 1		
	8517	Lynch syndrome	MLH1, MSH2, MSH6, PMS2 + EPCAM del/dup		9024	NF2	Neurofibromatosis type 2		
	8508	MLH1	Lynch syndrome		5426	RB1	Hereditary retinoblastoma		
	8510	MSH2 + EPCAM del/dup	Includes MSH2 inversion		7180	SMARCB1	Schwannomatosis		
	2226	MSH2 inversion	Lynch syndrome		8022	CASR, CFTR, CPA1, PRSS1,	Pancreatitis panel		
	8512	MSH6	Lynch syndrome	Other C	Ordora	SPINK1, CTRC	'		
	4661	MUTYH	MUTYH-associated polyposis	Other		visit ambrygen.com for a list	t of available tests		
	4646	PMS2	Lynch syndrome						
	2766					ode(s): Gene	e/Test Name(s):		
SPECIFIC	SITE A	NALYSIS (Please include a	copy of relative's report)						
Gene(s): Mutation(s): Rel			Relationship to Relative:Accession # (if tested at Ambry):						
			Positive c	Positive control sample: ☐ will be provided ☐ already at Ambry ☐ not available					



Patient Name:	DOB:
---------------	------

Supplemental Information

Hereditary Cancer Multi-Gene Tests

TEST NAME TEST CODE GENES							
Pan-cancer	'						
CancerNext® (39 genes)	8824	APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, EPCAM, FH, FLCN, GREM1, HOXB13, MBD4, MET, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53, TSC1, TSC2, VHL					
CancerNext- <i>Expanded</i> ® (76 genes or up to 90 genes w/	8875	AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, DDX41, DICER1, EGFR, EPCAM, ETV6, FH, FLCN, GATA2, GREM1, HOXB13, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RET, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WT1					
add-ons)		Optional Add-on 1 - Limited Evidence Genes (9 genes): ATRIP, EGLN1, KIF1B, MLH3, PALLD, RAD51B, RNF43, RPS20, TERT					
		Optional Add-on 2 - Pancreatitis Genes (5 genes): CFTR, CPA1, CTRC, PRSS1, SPINK1					
STAT Breast Management							
BRCAPlus® (13 genes)	8836	ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53					
Breast & gynecologic							
BRCANext® (19 genes or up to 26	8857	ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TPS3					
genes w/ add-on)		Optional Add-on - Limited Evidence Genes (7 genes): ATRIP, CDC73, FH, NTHL1, POLD1, POLE, RAD51B					
Colorectal & polyposis	ı						
ColoNext® (20 genes or up to 26	8821	APC, AXIN2, BMPR1A, CDH1, EPCAM, GREM1, MBD4, MLH1, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53					
genes w/ add-on)		Optional Add-on - Limited Evidence Genes (6 genes): ATM, CHEK2, CTNNA1, MLH3, RNF43, RPS20					
Customizable							
		To order all genes on Ambry's oncology menu, please order CancerNext-Expanded.					
CustomNext-Cancer® (up to 90 genes) Required: complete CustomNext-Cancer supplemental form. ambrygen.com/forms	9511	AIP, ALK, APC, ATM, ATRIP, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CEBPA, CFTR, CHEK2, CPA1, CTNNA1, CTRC, DICER1, DDX41, EGFR, ELGN1, EPCAM, ETV6, FH, FLCN, GATA2, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NF1, NF2, NTHL1, PALB2, PALLD, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PRSS1, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RET, RNF43, RPS20, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SPINK1, STK11, SUFU, TERT, TMEM127, TPS3, TSC1, TSC2, VHL, WT1					
		For Medicare Patients: At a minimum, the following core genes must be included in the panel to ensure Medicare coverage: APC, ATM, BRCA1, BRCA2, CHEK2, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, TP53.					
Syndrome specific							
Adenomatous polyposis	8726	APC, MUTYH					
BRCA1/2-associated hereditary breast and ovarian cancer (HBOC)	8838	BRCA1, BRCA2					
Lynch syndrome	8517	MLH1, MSH2, MSH6, PMS2 + EPCAM del/dup					

Specimen Requirements

Blood/saliva from patients with a history of allogenic bone marrow or stem cell transplant cannot be used for genetic testing. Blood/saliva from patients with active hematological disease is not recommended. An alternative specimen may be needed. Please see ambrygen.com/specimen-requirements for details.